Journal
BLOOD
Volume 115, Issue 12, Pages 2407-2411Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-08-237123
Keywords
-
Categories
Funding
- Pfizer
- Fundacao para a Ciencia e Tecnologia [PTDC/SAU-MII/71662/2006]
- Fundacao Calouste Gulbenkian [99293]
- Human Frontier Science Program
- Fundacao Luso-Americana para o Desenvolvimento
- Fundacaopara a Ciencia e Tecnologia (FCT) [PTDC/SAU-MII/69280/2006, PTDC/SAU-MII/78333/2006, 47342/2008, 37898/2007]
- Fundação para a Ciência e a Tecnologia [PTDC/SAU-MII/69280/2006, PTDC/SAU-MII/71662/2006, PTDC/SAU-MII/78333/2006] Funding Source: FCT
Ask authors/readers for more resources
On the path to successful immunotherapy of hematopoietic tumors, gamma delta T cells offer great promise because of their human leukocyte antigen (HLA)-unrestricted targeting of a wide variety of leukemias/lymphomas. However, the molecular mechanisms underlying lymphoma recognition by gamma delta T cells remain unclear. Here we show that the expression levels of UL16-binding protein 1 (ULBP1) determine lymphoma susceptibility to gamma delta T cell-mediated cytolysis. Consistent with this, blockade of NKG2D, the receptor for ULBP1 expressed on all V gamma 9+ T cells, significantly inhibits lymphoma cell killing. Specific loss-of-function studies demonstrate that the role of ULBP1 is nonredundant, highlighting a thus far unique physiologic relevance for tumor recognition by gamma delta T cells. Importantly, we observed a very wide spectrum of ULBP1 expression levels in primary biopsies obtained from lymphoma and leukemia patients. We suggest this will impact on the responsiveness to gamma delta T cell-based immunotherapy, and therefore propose ULBP1 to be used as a leukemia/lymphoma biomarker in upcoming clinical trials. (Blood. 2010;115:2407-2411)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available